| To: richardred who wrote (2596) | 12/13/2010 12:52:36 PM | | From: richardred | | | | DJ MARKET TALK: Street Mulls Size Of Next Verigy Bid
blue line
Source: DJ
Date: 08:15 AM
12/13 08:15 DJ MARKET TALK: Street Mulls Size Of Next Verigy Bid
8:15 (Dow Jones) Disparate views on the Street over the size of Advantest's next bid for Verigy (VRGY). Barclays ups VRGY to equalweight: "We believe Advantest will come in with a higher bid for Verigy"; says final offer likely to be in $15-$18 range. Meanwhile, Stifel Nicolaus cuts VRGY to hold, says Advantest's next bid will likely close the deal at only a "modest premium" above last week's $12.15/share bid, which VRGY rejected. "Although we believe that the company has a fair value of $16-17, we do not believe that Advantest needs to reach that price level." VRGY closed Friday at $13.25. (christopher.dieterich@ dowjones.com) |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: richardred who wrote (2584) | 12/13/2010 1:20:44 PM | | From: richardred | | | | Billionaire buys stake in EXCO Resources
Billionaire Wilbur Ross buys 7.5 percent stake in EXCO Resources
On Monday December 13, 2010, 10:55 am EST
NEW YORK (AP) -- Billionaire investor Wilbur L. Ross has purchased a stake in independent oil and gas company EXCO Resources Inc. and may want to discuss "extraordinary corporate transactions, such as a merger."
Ross' company, WL Ross & Co., notified the Securities and Exchange Commission Friday that it bought a 7.5 percent stake in EXCO. EXCO, based in Dallas, develops oil and gas fields in Texas, Louisiana, Appalachia and other parts of the U.S. Last month, CEO Douglas H. Miller announced plans to take the company private, offering $20.50 per share.
Calls to Ross's office and EXCO were not returned Monday morning.
EXCO controls about 1 trillion cubic feet of proven gas reserves and has struggled with low natural gas prices that have made some of its operations unprofitable. Its shares tumbled to a 52-week low of $13.25 in September.
They added 66 cents, or 3.6 percent, at $19.17 in morning trading.
finance.yahoo.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: richardred who wrote (2629) | 12/13/2010 11:20:27 PM | | From: Paul Senior | | | | Added to my EXCO position today based on that, fwiw.
Too many pro's now in that stock for the company not to be a buyout. At what price though, I don't know. So a buyer's gain now from the stock's current price might not be so great. |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: richardred who wrote (2274) | 12/14/2010 12:52:02 AM | | From: richardred | | | | UPDATE 2-Galderma bids $967 mln for Swedish implant firm Q-Med
By Helena Soderpalm
STOCKHOLM, Dec 13 (Reuters) - Galderma, a joint venture between L'Oreal (OREP.PA) and Nestle (NESN.VX), launched a bid for Sweden's Q-Med (QMED.ST) for about $970 million, creating a bigger rival in anti-ageing treatments to Botox maker Allergan Inc (AGN.N).
Cosmetic surgery is growing massively across the world with Botox and other facial filler treatments among the most popular procedures. [ID:nN14151304]
Buying Q-Med would give Galderma access to the Swedish firm's Restylane product, an alternative to Botox for smoothing out wrinkles and making faces look plumper and younger.
Q-Med also produces a gel that is used in breast enlargement and body contouring without the need for surgery.
Galderma, which makes products aimed at treating skin, hair and nail diseases like acne, psoriasis and skin cancer, said the offer was worth around 75 crowns per share.
It values Q-Med at 32.9 times earnings per share in the 12 months to end-September. That compares with a price-to-earnings ratio of about 22 times at Allergan, and 12.2 times at U.S. partner Medicis, according to Thomson Reuters data.
Medicis Pharmaceutical Corp (MRX.N) sells Restylane in North America.
"We have called the 10 biggest owners to tell them about the offer and have had a positive reaction," Anders Milton, a director and Chairman of the bid committee at Q-Med said.
Shares in Q-Med, which made a pretax profit of 756 million Swedish crowns on revenues of 1.4 billion in 2009, were up 12.8 percent at 74.75 crowns at 1238 GMT, indicating the market belives that the deal will go through.
reuters.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: richardred who wrote (2614) | 12/14/2010 11:10:56 AM | | From: richardred | | | | Cypress Board Rejects Ramius' $6.00 All-Cash Offer
Announces Intention to Increase Tender Offer to $6.00 Per Share in Cash
prnewswire
Press Release Source: Ramius LLC On Tuesday December 14, 2010, 10:51 am
NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Ramius V&O Acquisition LLC, a subsidiary of Ramius LLC (collectively, "Ramius"), today announced that Cypress Bioscience, Inc. (Nasdaq:CYPB - News) has rejected its fully financed offer to acquire all of Cypress' outstanding Common Stock in a negotiated transaction for $6.00 per share in cash.
Ramius and affiliates of Royalty Pharma Finance Trust ("Royalty Pharma") had fully negotiated the terms of a definitive merger agreement with Cypress over the past few days and in connection therewith increased their offer to acquire all of Cypress' outstanding Common Stock to $6.00 per share in cash. Yesterday, Ramius and Royalty Pharma were led to believe that the revised offer would likely be acceptable to the Board of Directors of Cypress and that the Board would be meeting last night to consider the revised offer.
Unfortunately, Ramius and Royalty Pharma learned Monday night that the Board had rejected its offer and that the Company is pursuing an alternative transaction with a third party. Ramius and Royalty Pharma believe that the Company is now considering a less certain, alternative transaction with this third party.
In light of the foregoing, Ramius intends to promptly amend its current tender offer to increase the offer price to $6.00 per share in cash and, among other things, to eliminate the financing condition.
Ramius currently owns 9.9% of Cypress and commenced a tender offer on September 15, 2010 to purchase all of the shares of Cypress it does not currently own for $4.25 per share.
Ramius urges the members of the Cypress Board to carefully consider their fiduciary duties to Cypress' stockholders and to give Cypress stockholders an opportunity to choose which transaction they prefer. In particular, Ramius urges the Cypress Board not to agree to any break-up fee with the other party or any other terms that are disadvantageous to Ramius and Cypress' stockholders.
For further information regarding Ramius' tender offer, shareholders can visit www.tenderforcypressbio.com. Otherwise, to contact Ramius directly, stockholders can email contact information to cypbtender@ramius.com.
IMPORTANT INFORMATION REGARDING THE TENDER OFFER
Ramius V&O Acquisition LLC, a wholly-owned subsidiary of Ramius Value and Opportunity Advisors LLC, has commenced, along with certain of its affiliates, a tender offer to purchase all of the outstanding shares of common stock of Cypress at $4.25 per share, net to the seller in cash, without interest. The offer is now scheduled to expire at 12:00 Midnight, New York City time, on December 17, 2010, unless the offer is extended.
Innisfree M&A Incorporated is the Information Agent for the tender offer and any questions or requests for the Offer to Purchase and related materials with respect to the tender offer may be directed to Innisfree M&A Incorporated.
THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL ANY SHARES. THE SOLICITATION AND THE OFFER TO BUY CYPRESS' COMMON STOCK IS ONLY BEING MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS THAT RAMIUS VALUE AND OPPORTUNITY ADVISORS LLC HAS FILED (AND WILL FILE) WITH THE SECURITIES AND EXCHANGE COMMISSION. STOCKHOLDERS SHOULD READ THESE MATERIALS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. STOCKHOLDERS MAY OBTAIN THE OFFER TO PURCHASE AND RELATED MATERIALS WITH RESPECT TO THE TENDER OFFER FREE AT THE SEC'S WEBSITE AT WWW.SEC.GOV/ OR FROM RAMIUS LLC BY CONTACTING INNISFREE M&A INCORPORATED TOLL-FREE AT (877) 717-3936 OR COLLECT AT (212) 750-5833.
The offer is now scheduled to expire at 12:00 Midnight, New York City time, on December 17, 2010, unless extended.
About Ramius LLC
Ramius LLC is a registered investment advisor that manages assets in a variety of alternative investment strategies. Ramius LLC is headquartered in New York with offices located in London, Luxembourg, Tokyo, Hong Kong and Munich.
Contact:
Ramius LLC
Peter Feld, 212-201-4878
Gavin Molinelli, 212-201-4828
Follow Yahoo! Finance on Twitter; become a fan on Facebook.
finance.yahoo.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: richardred who wrote (2633) | 12/15/2010 11:02:13 AM | | From: richardred | | | | Cypress jumps on buyout deal
BOSTON (MarketWatch) -- Cypress Bioscience /quotes/comstock/15*!cypb/quotes/nls/cypb (CYPB 6.46, +0.71, +12.32%) shares jumped 12% to $6.47 early Wednesday on news that it has agreed to be acquired by Ramius V&O Acquisition LLC and Royalty Pharma for $6.50 a share, or $255 million. Ramius, which already owns shares of Cypress, said the buyout price represents a 160% premium over Cypress' last closing price before Ramius disclosed it was interested in buying the biotech company in mid-July.
marketwatch.com |
| | Speculating in Takeover Targets | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
